A New Drug Halves Migraine Days in Patients with No Other Options
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
A Spanish study shows that 30% of these patients manage to halve the days of seizures with this treatment.
A study led by Bellvitge University Hospital has shown that the new drug atogepant halves the days of pain in 30% of patients with refractory migraine, providing a new alternative for those who have exhausted all previous preventive options. Read more]]>
The Bellvitge University Hospital, located in Hospitalet de Llobregat, and the Bellvitge Biomedical Research Institute (Idibell) have led a multicenter study in real clinical practice that demonstrates the efficacy of atogepant in cases of highly complex migraine. The research, published in The Journal of Headache and Pain with the collaboration of 17 hospitals from around […] The entry Atogepant reduces the impact of refractory migraine, one of…
Noticias de Navarra
A study led by Bellvitge University Hospital has shown that the new drug atogepant halves the days of pain in 30% of patients with refractory migraine, providing a new alternative for those who have exhausted all previous preventive options.
Migraine is one of the main causes of disability in the world. In Spain it is estimated that it affects around 12% of the population. This impact reinforces the need to move towards more personalized models that allow better assessment of the real benefits of treatments. Despite the advances achieved in recent years, there are people who, having tried all the preventive treatments available, continue to suffer migraine almost daily. This study p…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
